SAEN Genenta Science S.p.A. Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1838716 · Reporting currency EUR
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY26.7%
TTM EPS YoY32.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-38.0%
ROA-28.0%
ROIC (approx.)-43.1%
Asset turnover—
Leverage & solvency
Liabilities / assets31.5%
Debt / equity0.00x
Current ratio14.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.05x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 2.70M | 4.81M | 6.47M | 5.34M | 3.39M |
| SG&A expense | 3.90M | 4.95M | 5.26M | 5.71M | 2.30M |
| Operating income | -6.60M | -9.76M | -11.73M | -11.04M | -5.69M |
| Pretax income | -6.53M | -8.91M | -11.65M | -8.48M | -5.53M |
| Net income | -6.53M | -8.91M | -11.65M | -8.48M | -5.53M |
| EBITDA | -6.58M | -9.72M | -11.69M | -11.04M | -5.68M |
| EPS (basic) | — | — | -0.64 | -0.47 | -0.37 |
| EPS (diluted) | -0.33 | -0.49 | -0.64 | -0.47 | -0.37 |
| Weighted avg. shares (diluted) | 19.71M | 18.27M | 18.22M | 18.22M | 15.08M |
| Balance sheet | |||||
| Cash & equivalents | 5.53M | 4.58M | 3.69M | 29.79M | 37.24M |
| Short-term investments | 22.62M | 8.08M | 15.08M | — | — |
| Current assets | 29.98M | 14.47M | 21.26M | 31.72M | 38.76M |
| PP&E, net | 22,465 | 42,922 | 82,977 | 111,639 | 23,090 |
| Intangibles | — | — | — | 87,000 | — |
| Total assets | 31.89M | 14.82M | 22.35M | 33.44M | 40.03M |
| Current liabilities | 2.12M | 2.10M | 1.74M | 2.18M | 1.14M |
| Total liabilities | 10.05M | 2.33M | 1.91M | 2.30M | 1.17M |
| Shareholders' equity | 21.84M | 12.50M | 20.43M | 31.14M | 38.86M |
| Shares outstanding | 23.43M | 18.29M | 18.22M | 18.22M | 18.22M |
| Cash flow statement | |||||
| Operating cash flow | -6.87M | -6.24M | -11.21M | -7.42M | -6.96M |
| Capital expenditure | 7,625 | 4,468 | 13,791 | 27,070 | 9,009 |
| Free cash flow | -6.88M | -6.24M | -11.22M | -7.45M | -6.97M |
| Investing cash flow | -14.54M | 6.88M | -14.89M | -27,070 | -9,009 |
| Financing cash flow | 22.29M | 270,885 | 531 | — | 28.74M |
| Depreciation & amortization | 28,082 | 44,523 | 42,453 | 6,140 | 4,889 |
| Stock-based compensation | 1.01M | 847,255 | 739,884 | 722,735 | 497,104 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.